{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:51:24Z","timestamp":1793242284283,"version":"4.5.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mycosis Fungoides (MF) is a common subtype of primary cutaneous T-cell lymphoma (CTCL), a group of non-Hodgkin lymphomas. The clinical spectrum of MF ranges from isolated cutaneous lesions to widespread involvement of lymph nodes, blood, and skin, as seen in its aggressive variant, S\u00e9zary Syndrome (SS). Mogamulizumab, a defucosylated humanized IgG1-\u03ba anti-CCR4 monoclonal antibody approved for relapsed\/refractory MF\/SS, has demonstrated a favorable safety and efficacy profile in multiple case series.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, monocentric observational study analyzed data from 12 patients treated with Mogamulizumab between January 1, 2019, and December 31, 2024. We aim to evaluate the tolerability and clinical response to Mogamulizumab in patients with MF\/SS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 12 patients treated, 8 had MF and 4 had SS. The median follow-up time was 29.9 months (range 2.8\u201368.6 months). Four patients discontinued mogamulizumab: 3 due to disease progression and 1 due to the development of breast cancer. Adverse events included MAR in 4 patients (33%) and colitis in 1 patient (6%). The observed median PFS after mogamulizumab therapy was 5.4 months, and the observed ORR was 50%. For all 12 patients, the median time to response (TTR) was 129 days. The observed median overall survival (OS) was 11.5 months, with 1 reported death due to septic shock in a patient who underwent salvage allo-HSCT after mogamulizumab failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of this study reaffirm the efficacy of Mogamulizumab therapy for patients with Mycosis Fungoides and S\u00e9zary Syndrome in a real-world setting, which involves treatment decisions that must often consider patient heterogeneity, comorbidities, and prior lines of therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1748746","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:56:01Z","timestamp":1769064961000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and tolerability of mogamulizumab in mycosis fungoides and S\u00e9zary Syndrome: a monocentric retrospective study"],"prefix":"10.3389","volume":"15","author":[{"given":"Antonio","family":"Giordano","sequence":"first","affiliation":[{"name":"Department of Hematology, Fondazione Policlinico Universitario Agostino Gemelli \u2013 IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Fianchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fondazione Policlinico Universitario Agostino Gemelli \u2013 IRCCS","place":["Rome, Italy"]},{"name":"Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Criscuolo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fondazione Policlinico Universitario Agostino Gemelli \u2013 IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Quattrone","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fondazione Policlinico Universitario Agostino Gemelli \u2013 IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Di Pilla","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fondazione Policlinico Universitario Agostino Gemelli \u2013 IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Pagano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fondazione Policlinico Universitario Agostino Gemelli \u2013 IRCCS","place":["Rome, Italy"]},{"name":"Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.5045\/br.2023.2023023","article-title":"Mycosis fungoides and S\u00e9zary syndrome","volume":"58","author":"Lee","year":"2023","journal-title":"Blood Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1141108","article-title":"Mycosis fungoides and S\u00e9zary syndrome: clinical presentation, diagnosis, staging, and therapeutic management","volume":"13","author":"Miyashiro","year":"2023","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.humpath.2023.06.001","article-title":"Primary cutaneous T-cell lymphoma: a review of the most common entities with focus on recent updates","volume":"138","author":"Saleh","year":"2023","journal-title":"Hum Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04","article-title":"Oncogenomic analysis of mycosis fungoides reveals major differences with S\u00e9zary syndrome","volume":"113","author":"Van Doorn","year":"2009","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.8","article-title":"Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes","volume":"130","author":"Laharanne","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2022.104126","article-title":"Primary cutaneous lymphoma: the 2018 update of the WHO-EORTC classification","volume":"51","author":"Willemze","year":"2022","journal-title":"Presse Medicale"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2022.029","article-title":"The treatment of advanced-stage mycosis fungoides and sezary syndrome: a hematologist\u2019s point of view","volume":"14","author":"Giordano","year":"2022","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and S\u00e9zary syndrome with alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"Eur J Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S \u00b4 ezary syndrome: A multicenter phase II study","volume":"38","author":"Khodadoust","year":"2019","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20708","article-title":"Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series*","volume":"186","author":"Trum","year":"2022","journal-title":"Br J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012057","article-title":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","author":"Olsen","year":"2022","journal-title":"Blood 419\u2013437"},{"key":"B15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.26760","article-title":"Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Hristov","year":"2023","journal-title":"Am J Hematol"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071659","article-title":"Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study","author":"Jouandet","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.19134","article-title":"Effectiveness of mogamulizumab in patients with Mycosis Fungoides or S\u00e9zary syndrome: A multicentre, retrospective, real-world French study","author":"Beylot-Barry","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1748746\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:56:02Z","timestamp":1769064962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1748746\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":17,"alternative-id":["10.3389\/fonc.2025.1748746"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1748746","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"article-number":"1748746"}}